Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylactic factor replacement in hemophilia.

Manuel D Carcao1, Louis Aledort

  • 1Department of Paediatrics, Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Canada.

Blood Reviews
|March 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hb F-SickKids (<i>HBG2</i>: C.308A > G): A Novel γ-Globin Variant Associated with Transient Neonatal Cyanosis.

Hemoglobin·2026
Same author

Prevention, Identification, Management and Long-Term Complications of Intracranial Haemorrhage in Children With Haemophilia and Other Severe Bleeding Disorders-A Practical Guidance.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Challenges associated with access to recently developed hemophilia treatments in routine care: perspectives of healthcare professionals.

Haematologica·2024
Same author

Professor Victor S. Blanchette, MA, MB, BChir (Cantab), FRCP(C), FRCP (1945-2024).

Journal of thrombosis and haemostasis : JTH·2024
Same author

Unravelling the effect of blood group on FVIII:C levels and response to DDAVP in 20 males with a single genotype (Twillingate Variant) causing Haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same author

Long-term follow-up of patients with congenital thrombotic thrombocytopenia purpura receiving a plasma-derived factor VIII (Koate) that contains ADAMTS13.

Haemophilia : the official journal of the World Federation of Hemophilia·2023
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Regular infusions of clotting factor concentrates, known as prophylaxis, have evolved over 30 years for severe hemophilia management. This review discusses prophylaxis evolution, benefits, risks, and addresses key questions in hemophilia care.

Area of Science:

  • Hematology
  • Thrombosis and Hemostasis
  • Pediatric Hematology

Background:

  • Prophylaxis involves regular infusions of coagulation factor concentrates for severe hemophiliacs.
  • This management strategy has been evolving over the past three decades.
  • Numerous clinical trials investigate optimal prophylaxis regimens, benefits, risks, and costs.

Purpose of the Study:

  • To present a detailed review of the evolution of prophylaxis in hemophilia management.
  • To discuss the major issues and unanswered questions surrounding prophylaxis.
  • To provide insights into optimal patient selection, timing, and duration of prophylaxis.

Main Methods:

  • Comprehensive literature review of clinical trials and studies on hemophilia prophylaxis.

Related Experiment Videos

  • Analysis of the historical development and current state of prophylactic therapy.
  • Discussion of unresolved clinical questions regarding prophylaxis initiation and cessation.

    • Main Results:

    • Prophylaxis has significantly evolved as a therapeutic tool over 30 years.
    • Ongoing research aims to define ideal prophylaxis regimens and address patient-specific questions.
    • Key issues include determining who should receive prophylaxis, when to initiate, and when to stop.

    Conclusions:

    • Prophylaxis is a cornerstone in managing severe hemophilia, with continuous refinement of treatment strategies.
    • Further research is essential to optimize prophylaxis and answer critical clinical questions for improved patient outcomes.
    • Addressing the complexities of prophylaxis ensures better long-term management for individuals with hemophilia.